PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 69.82

Change

+0.01 (+0.01)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.04% 7% C- 45% F
Dividend Return 0.05% 9% A- 1% F
Total Return 6.09% 7% C- 36% F
Trailing 12 Months  
Capital Gain 24.16% 74% C 64% D
Dividend Return 0.06% 8% B- 2% F
Total Return 24.22% 74% C 56% F
Trailing 5 Years  
Capital Gain 50.22% 45% F 69% C-
Dividend Return 0.10% 8% B- 1% F
Total Return 50.32% 40% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 6.08% N/A N/A 59% D-
Dividend Return 6.09% N/A N/A 51% F
Total Return 0.01% N/A N/A 1% F
Risk Return Profile  
Volatility (Standard Deviation) 21.01% N/A N/A 49% F
Risk Adjusted Return 28.99% N/A N/A 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike